These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 15540922)
1. Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma. Saito R; Bringas J; Mirek H; Berger MS; Bankiewicz KS J Neurosurg; 2004 Nov; 101(5):826-31. PubMed ID: 15540922 [TBL] [Abstract][Full Text] [Related]
2. Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors. Zhang RX; Dougherty DV; Rosenblum ML Chin Med J (Engl); 1990 Aug; 103(8):658-65. PubMed ID: 2122945 [TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells. Horvath Z; Höchtl T; Bauer W; Fritzer-Szekeres M; Elford HL; Szekeres T; Tihan T Cancer Chemother Pharmacol; 2004 Aug; 54(2):139-45. PubMed ID: 15133626 [TBL] [Abstract][Full Text] [Related]
4. Predicting and monitoring response to chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea in subcutaneously implanted 9L glioma using the apparent diffusion coefficient of water and 23Na MRI. Babsky AM; Hekmatyar SK; Zhang H; Solomon JL; Bansal N J Magn Reson Imaging; 2006 Jul; 24(1):132-9. PubMed ID: 16758478 [TBL] [Abstract][Full Text] [Related]
5. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548 [TBL] [Abstract][Full Text] [Related]
6. Measurement of sister chromatid exchange induction in intracerebral brain tumors as a method for evaluation of therapeutic drug combinations. Bodell WJ Anticancer Res; 2000; 20(5A):3099-103. PubMed ID: 11062728 [TBL] [Abstract][Full Text] [Related]
7. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. Kim GY; Tyler BM; Tupper MM; Karp JM; Langer RS; Brem H; Cima MJ J Control Release; 2007 Nov; 123(2):172-8. PubMed ID: 17884232 [TBL] [Abstract][Full Text] [Related]
8. [Studies on the mechanism of ACNU resistance in sublines of rat C6 glioma and 9L gliosarcoma in vitro]. Yoshida T; Shimizu K; Ushio Y; Hayakawa T; Kato A; Mogami H; Sakamoto Y No Shinkei Geka; 1986 Oct; 14(11):1299-304. PubMed ID: 3468375 [TBL] [Abstract][Full Text] [Related]
9. Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Smith MT; Evans CG; Doane-Setzer P; Castro VM; Tahir MK; Mannervik B Cancer Res; 1989 May; 49(10):2621-5. PubMed ID: 2713846 [TBL] [Abstract][Full Text] [Related]
10. The role of minocycline in the treatment of intracranial 9L glioma. Weingart JD; Sipos EP; Brem H J Neurosurg; 1995 Apr; 82(4):635-40. PubMed ID: 7897527 [TBL] [Abstract][Full Text] [Related]
11. Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea. Hank NC; Shapiro JR; Scheck AC BMC Cancer; 2006 Jan; 6():2. PubMed ID: 16393339 [TBL] [Abstract][Full Text] [Related]
12. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. Storm PB; Renard VM; Moriarity JL; Tyler B; Wilentz RE; Brem H; Weingart JD Cancer Chemother Pharmacol; 2004 Oct; 54(4):361-7. PubMed ID: 15197484 [TBL] [Abstract][Full Text] [Related]
13. Effect of caffeine on cytotoxicity and sister chromatid exchange induction in sensitive and resistant rat brain tumor cells treated with 1,3-bis(2-chloroethyl)-1-nitrosourea. Aida T; Bodell WJ Cancer Res; 1987 Oct; 47(19):5052-8. PubMed ID: 3621190 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma. Lee JS; An TK; Chae GS; Jeong JK; Cho SH; Lee HB; Khang G Eur J Pharm Biopharm; 2005 Jan; 59(1):169-75. PubMed ID: 15567315 [TBL] [Abstract][Full Text] [Related]
15. Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain. Khil MS; Kolozsvary A; Apple M; Kim JH Int J Radiat Oncol Biol Phys; 2000 May; 47(2):511-6. PubMed ID: 10802380 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer. Chae GS; Lee JS; Kim SH; Seo KS; Kim MS; Lee HB; Khang G Int J Pharm; 2005 Sep; 301(1-2):6-14. PubMed ID: 16024190 [TBL] [Abstract][Full Text] [Related]
17. Reduced level of DNA cross-links and sister chromatid exchanges in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant rat brain tumor cells. Bodell WJ; Rupniak HT; Rasmussen J; Morgan WF; Rosenblum ML Cancer Res; 1984 Sep; 44(9):3763-7. PubMed ID: 6744295 [TBL] [Abstract][Full Text] [Related]
18. Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells. Yan YR; Xie Q; Li F; Zhang Y; Ma JW; Xie SM; Li HY; Zhong XY Neuropathology; 2014 Apr; 34(2):128-34. PubMed ID: 24112388 [TBL] [Abstract][Full Text] [Related]
19. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Tamargo RJ; Myseros JS; Epstein JI; Yang MB; Chasin M; Brem H Cancer Res; 1993 Jan; 53(2):329-33. PubMed ID: 8417826 [TBL] [Abstract][Full Text] [Related]
20. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]